C. difficile diagnostics

Clostridium difficile is the major cause of nosocomial diarrhea and pseudomembranous colitis

C. difficile infection usually occurs when the normal microflora of the intestinal tract is altered or killed by antibiotics. Once C. difficile growth begins, toxins A and B are produced, causing diarrhea and colitis.

The disease can be treated with metronidazole or vancomycin, but relapses occur in about 20% of patients who develop the infection.

TECHLAB produces a panel of in vitro diagnostics for detecting C. difficile and its toxins in fecal specimens from patients suspected of having the disease.

How to buy TECHLAB® diagnostics

Product NameCatalog #Suggested CPT Code*Tests/KitAnalyte(s) DetectedFormatTime to ResultFecal Sample Type
C. DIFF QUIK CHEK COMPLETE®T30525C/T30550C
30525C/30550C T30525C-J
87324 and
87449
25 or
50
Toxins A&B GDHRapid EIA< 30 minFresh fecal sample (unpreserved) / Cary Blair / C&S
C. DIFF QUIK CHEK®T5029/303908744925GDHRapid EIA< 30 minFresh fecal sample (unpreserved)
TOX A/B QUIK CHEK®T5033/303948732425Toxins A&BRapid EIA< 30 minFresh fecal sample (unpreserved) / Cary Blair / C&S
C. DIFF CHEK™- 60T5025/
30392 T5025B/
30392B T30392SKG
8744996GDHMicroplate ELISA1hr, or 30 min
(rapid format)
Fresh fecal sample (unpreserved)
C. DIFFICILE TOX A/B II™T5015/30397
T5015B/30397B T30397SKG
8732496Toxins A&BMicroplate ELISA1hr, or 30 min
(rapid format)
Fresh fecal sample (unpreserved)
C. difficile Toxin/Antitoxin KitT500087230300-
650
Toxin BTissue Culture18 hrsFresh fecal sample (unpreserved)
C. DIFFICILE TOX-B TESTT5003/30399U8723096Toxin BTissue Culture24-48hrsFresh fecal sample (unpreserved) / Cary Blair / C&S

† For state by state fee schedule go to www.cms.hhs.gov

Under Federal and State law, it is the individual provider’s responsibility to determine appropriate coding, charges and claims for a particular service. Policies regarding appropriate coding and payment levels can vary greatly from payer to payer and change over time. TECHLAB/Alere strongly recommends that providers contact their contracted payers to determine the appropriate coding and charge or payment levels prior to submitting claims.

 

Further Reading

Importance of stool toxin testing by J.H. Boone, TECHLAB®

Evaluation of diagnostic tests for Clostridium difficile infection by Jonathan Swindells, Nigel Brenwald, Nathan Reading, and Beryl Oppenheim, Journal of Clinical Microbiology

C. Diff Quik Chek Complete enzyme immunoassay provides a reliable first-line method for detection of Clostridium difficile in stool specimens by Criziel D. Quinn, Susan E. Sefers, Wisal Babiker, Ying He, Romina Alcabasa, Charles W. Stratton, Karen C. Carroll, and Yi-Wei Tang, Journal of Clinical Microbiology